Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated February 11, 2026, "OneSource-Hikma partnership secures approval tocommercialise generic version of Ozempic® in Saudi Arabia".
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Onesource Specialty Pharma has informed the stock exchange about a press release dated February 11, 2026. The company, through its partnership with Hikma, has secured regulatory approval to commercialise a generic version of Ozempic® in Saudi Arabia. Ozempic (semaglutide) is a blockbuster injectable drug used for type 2 diabetes and weight management, originally marketed by Novo Nordisk. This approval marks OneSource's entry into the high-demand GLP-1 segment in the Middle East, leveraging Hikma's established distribution network in the region. No specific revenue guidance or launch timeline was disclosed in the filing.
Positive development for shareholders as it opens a new, potentially high-margin revenue stream in a growing therapeutic category. The generic GLP-1 opportunity in the Middle East could contribute to future earnings, though investors should watch for actual launch timelines and commercial uptake.